Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III immunogenicity and safety study of Quinvaxem in Indian infants
2014-005309-18Phase 3
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Quinvaxem in diphtheria, Tetanus, pertussis and 2 more, sponsored by Novartis. Primary endpoint: Short-term anti-PRP seroprotection rate.
02
Drugs
Quinvaxem
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2014-005309-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005309-18.